List of Iclusig drug patents

Iclusig is owned by Takeda Pharms Usa.

Iclusig contains Ponatinib Hydrochloride.

Iclusig has a total of 6 drug patents out of which 0 drug patents have expired.

Iclusig was authorised for market use on 14 December, 2012.

Iclusig is available in tablet;oral dosage forms.

Iclusig can be used as a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia, a method of treating chronic myelogenous leukemia; a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for the treatment of leukemias; a method for treating acute lymphoblastic leukemia, a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating chronic myeloid leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain, a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating chronic myeloid leukemia.

The generics of Iclusig are possible to be released after 12 December, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(3 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Dec, 2026

(3 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 18, 2023

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: A method of treating chronic myelogenous leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; A method for the treatment of leukemias; A method for treating acute lymphoblastic leukemia; A method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

How can I launch a generic of ICLUSIG before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic